Pazopanib in metastatic renal cancer: a “real-world” experience at National Cancer Institute “Fondazione G. Pascale”

Pazopanib in metastatic renal cancer: a “real-world” experience at National Cancer Institute “Fondazione G. Pascale”

Pazopanib is an oral angiogenesis inhibitor, currently approved for treatment of metastatic renal cell carcinoma (mRCC) and soft tissue sarcoma. The present study analyzed the outcomes of pazopanib in first-line treatment of mRCC, in a single Italian cancer center. In the light of the retrospective,...

Full description

Bibliographic Details
Main Authors: Sabrina Chiara Cecere, Sabrina Rossetti, Carla Cavaliere, Chiara Della Pepa, Marilena Di Napoli, Anna Crispo, Gelsomina Iovane, Raffaele Piscitelli, Domenico Sorrentino, Gennaro Ciliberto, Piera Maiolino, Paolo Muto, Sisto Perdonà, Massimiliano Berretta, Sandro Pignata, Gaetano Facchini, Carmine D'Aniello
Format: Article
Language:English
Published: Frontiers Media S.A. 2016-08-01
Series:Frontiers in Pharmacology
Subjects:
real-life
PFS
First-line
Pazopanib
MRCC
Online Access:http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00287/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00287/full

Similar Items